Search clinical trials for: Umeclidinium Bromide

Total 819 results

Chinese SLE Treatment And Research Group
Beijing Life oasis public service center

Not yet recruiting

A Study on the Prevention and Treatment of GIOP With Eldecalcitol (ELEGANT)

Rheumatoid Arthritis | Osteoporosis | Osteopenia

China
GlaxoSmithKline

Recruiting

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Asthma

United States, Canada, Argentina, Australia, Japan, Korea, Republic of, Taiwan
Samsung Medical Center

Recruiting

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Chronic Obstructive Pulmonary Disease | Non Small Cell Lung Cancer

Korea, Republic of
GlaxoSmithKline

Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Pulmonary Disease, Chronic Obstructive

China
Boehringer Ingelheim

Completed

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
GlaxoSmithKline

Completed

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Asthma

Poland, Romania, Russian Federation, United States, Canada
GlaxoSmithKline

Completed

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Pulmonary Disease, Chronic Obstructive

China, Korea, Republic of
GlaxoSmithKline
Q2 Solutions; York Bioanalytical Solution; BI Medical.Inc; SRL Mediserch.Inc; Parexel...

Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Japan
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
GlaxoSmithKline

Withdrawn

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study (LEGEND)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, Japan, Russian Federation, Spain, Germany, Mexico, Romania, Korea, Republic of, Poland, Italy, France
GlaxoSmithKline

Withdrawn

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Asthma
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
GlaxoSmithKline

Completed

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany, Spain, United States, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Chronic Obstructive Pulmonary Disease

United States
GlaxoSmithKline

Completed

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Estonia, Peru, Poland, France, Chile, Hungary, Italy, Slovakia
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
GlaxoSmithKline

Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Ukraine, United States, Estonia, South Africa, Sweden, Norway, Russian Federation, Korea, Republic of
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Russian Federation, Ukraine, United States, South Africa, Korea, Republic of, Romania, Canada, France, Italy, Chile, Denmark
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Romania, Ukraine, United States, Chile, Greece, Peru
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Mexico, Norway
GlaxoSmithKline

Completed

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, Spain, Netherlands, Hungary, Denmark, Poland, Czechia
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Pulmonary Disease, Chronic Obstructive

Germany, United States, Korea, Republic of, Czech Republic
GlaxoSmithKline

Completed

A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Pulmonary Disease, Chronic Obstructive

China
The First Affiliated Hospital of Soochow University
Soochow University

Recruiting

Repeated Transcranial Magnetic Stimulation Relieve Chronic Visceral Pain in IBS

Irritable Bowel Syndrome | Functional Magnetic Resonance Imaging | Repetitive Transcranial Magnetic Stimulation | Chronic Visceral Pain

China
ASST Fatebenefratelli Sacco

Not yet recruiting

A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy

Pain
University Hospital of Split

Recruiting

Measurement of Blood Loss in Adenotonsillectomy During General Anesthesia According to the Application of Nondepolarizing Muscle Relaxants

Anesthesia | Neuromuscular Blockade | Intraoperative Bleeding | Anesthesia Complication | Post Operative Hemorrhage | Intraoperative Blood Loss

Croatia
Brigham and Women's Hospital
Open Medicine Foundation

Not yet recruiting

LIFT: Life Improvement Trial (LIFT)

ME/CFS
Fundacio Privada Mon Clinic Barcelona
GlaxoSmithKline

Recruiting

ANTES B+ Clinical Trial (ANTES B+)

Chronic Obstructive Pulmonary Disease

Spain
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Elpen Pharmaceutical Co. Inc.

Not yet recruiting

QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt. (TRITON)

COPD
Oregon Health and Science University
Wake Forest University Health Sciences; University at Buffalo; University of...

Recruiting

Treating Respiratory Emergencies in Children Study (T-RECS)

Asthma in Children

United States
Ain Shams University

Recruiting

Effect of Hyoscine- Bromide on Duration of the First Stage of Labor

Labor

Egypt
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Yale University
Janssen Scientific Affairs, LLC

Not yet recruiting

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor (emo_to2)

Muscarinic Receptor Occupancy

United States
Leiden University Medical Center
NMD Pharma A/S

Recruiting

Pyridostigmine and Amifampridine for Myasthenia Gravis (IMPACT-MG)

Myasthenia Gravis

Netherlands
Cairo University

Not yet recruiting

How to Reduce Pain in Patients Undergoing Office Hysteroscopy.

Pain
Chiesi Farmaceutici S.p.A.
SGS S.A.

Recruiting

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma

Belgium

3

Subscribe